<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518306</url>
  </required_header>
  <id_info>
    <org_study_id>GMRx2-HTN-2020-PCT1</org_study_id>
    <nct_id>NCT04518306</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension</brief_title>
  <acronym>GMRx2_PCT</acronym>
  <official_title>Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Medicines PTY Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Medicines PTY Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent hypertension guidelines recommend combination therapy as initial treatment for many or&#xD;
      most patients. Several trials suggest triple low-dose combination therapy may be highly&#xD;
      effective in terms of achieving blood pressure control without increasing adverse effects.&#xD;
      This trial is designed to investigate the efficacy and safety of GMRx2 in participants with&#xD;
      high blood pressure compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TRIAL DRUG:&#xD;
&#xD;
      GMRx2: single pill combination of telmisartan/amlodipine/indapamide Dose version 1:&#xD;
      telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg Dose version 2: telmisartan 20&#xD;
      mg/amlodipine 2.5 mg/indapamide 1.25 mg I NDICATION: Hypertension&#xD;
&#xD;
      TRIAL TITLE:&#xD;
&#xD;
      Efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      To investigate the efficacy and safety of GMRx2 compared to placebo for the treatment of&#xD;
      hypertension.&#xD;
&#xD;
      INTERVENTION:&#xD;
&#xD;
      A 2-week single-blind placebo run-in will be followed by a 4-week double-blind period with&#xD;
      randomization to GMRx2 dose version 1, GMRx2 dose version 2 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>International, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in change in home SBP from baseline to Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in change in clinic seated mean SBP from baseline to Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in clinic seated mean DBP from baseline to Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinic seated mean SBP &lt;140 and DBP &lt;90 mmHg at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinic seated mean SBP &lt;130 and DBP &lt;80 mmHg at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in home seated mean DBP from baseline to Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in trough home seated mean SBP from baseline to week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in trough home seated mean DBP from baseline to week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with home seated mean SBP &lt;135 and DBP &lt;85 mmHg at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with home seated mean SBP &lt;130 and DBP &lt;80 mmHg at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of participants discontinued trial medication due to AE/SAE from baseline to Week 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of participants with an SAE from baseline to Week 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of participants with symptomatic hypotension from baseline to Week 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of participants with serum sodium concentration below 135 mmol/l at Week 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of participants with serum sodium concentration above 145 mmol/l at Week 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>4 weeks</time_frame>
    <description>• Percentage of participants with eGFR drop of over 30% from baseline to Week 4</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Triple ¼ (GMRx2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple ½ (GMRx2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Triple ¼ (GMRx2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Triple ½ (GMRx2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At screening visit&#xD;
&#xD;
               1. Provided signed consent to participate in the trial.&#xD;
&#xD;
               2. Adult aged ≥18 years.&#xD;
&#xD;
               3. Low predicted CV risk, such that short-term treatment with placebo is clinically&#xD;
                  acceptable: e.g. atherosclerotic CV disease risk of &lt;10% over 10-years as&#xD;
                  assessed by the Pooled Cohorts equation; or similar equation as recommended by&#xD;
                  local guidelines.&#xD;
&#xD;
               4. Clinic attended automated seated mean SBP (average of last 2 measurements&#xD;
                  calculated by the BP monitor);&#xD;
&#xD;
                    -  140-159 mmHg on no treatment, or,&#xD;
&#xD;
                    -  130-149 mmHg on 1 BP-lowering drug.&#xD;
&#xD;
               5. Any contraindication to trial medications, including 2-week placebo run-in and&#xD;
                  4-week trial medication with GMRx2 (dose version 1 or 2) or placebo.&#xD;
&#xD;
        At randomization visit&#xD;
&#xD;
          1. Home seated mean SBP 130-154 mmHg in the week before the randomization visit.&#xD;
&#xD;
          2. Adherence of 80-120% to placebo run-in.&#xD;
&#xD;
          3. Tolerated placebo run-in.&#xD;
&#xD;
          4. Adherence to home BP monitoring schedule: ≥3 days in the week before the randomization&#xD;
             visit and ≥1 day per week during the preceding weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  At screening visit&#xD;
&#xD;
               1. Receiving 2 or more BP-lowering drugs.&#xD;
&#xD;
               2. Clinic seated mean SBP ≥160 mmHg and/or DBP ≥100 mmHg.&#xD;
&#xD;
               3. Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy&#xD;
                  test during the trial and up to 30 days after the discontinuation of the trial&#xD;
                  medication or breastfeeding or of childbearing age and not using an acceptable&#xD;
                  method of contraception. Acceptable methods of birth control include hormonal&#xD;
                  prescription oral contraceptives, contraceptive injections, contraceptive patch,&#xD;
                  intrauterine device, double-barrier method (e.g. condoms, diaphragm, or cervical&#xD;
                  cap with spermicidal foam, cream, or gel), or male partner sterilization.&#xD;
                  Contraception should be used for at least 1 month before the screening visit and&#xD;
                  until the end of trial participation.&#xD;
&#xD;
               4. Not suitable for participation in a clinical trial according to local ethical or&#xD;
                  regulatory requirements related to severe acute respiratory syndrome&#xD;
                  coronavirus-2 (SARS-CoV-2).&#xD;
&#xD;
               5. Contraindication, including hypersensitivity (e.g. anaphylaxis or angioedema), to&#xD;
                  any of the 3 trial medications.&#xD;
&#xD;
               6. Current/history of transient ischemic attack, stroke, or hypertensive&#xD;
                  encephalopathy.&#xD;
&#xD;
               7. Current/history of acute coronary syndrome, unstable angina, myocardial&#xD;
                  infarction, percutaneous transluminal coronary revascularization, or coronary&#xD;
                  artery bypass graft.&#xD;
&#xD;
               8. Current/history of New York Heart Association class III and IV congestive heart&#xD;
                  failure.&#xD;
&#xD;
               9. Current/history of a known secondary cause of hypertension, such as primary&#xD;
                  aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.&#xD;
&#xD;
              10. Current/history of substantially uncontrolled diabetes (HbA1c &gt; 11.0%) within&#xD;
                  last three months.&#xD;
&#xD;
              11. Current/history of end-stage renal disease or anuria or estimated glomerular&#xD;
                  filtration rate (eGFR) &lt;60 ml/min/1.73m2.&#xD;
&#xD;
              12. Current/history of aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
                  (ALT) &gt;3 times the upper limit of normal range within 6 months.&#xD;
&#xD;
              13. Current concomitant illness or physical impairment or mental condition that in&#xD;
                  the judgment of the investigator could interfere with the effective conduct of&#xD;
                  the trial or constitutes a significant risk to the participants' well-being.&#xD;
&#xD;
              14. Arm circumference that is too large (&gt;55 cm) or too small (&lt;20 cm) to allow&#xD;
                  accurate measurement of BP.&#xD;
&#xD;
              15. Currently taking or might need during the trial, a concomitant treatment which is&#xD;
                  known to interact significantly with the trial medication: digoxin, lithium,&#xD;
                  diabetics receiving aliskiren, moderate and strong CYP3A4 inhibitors [e.g.&#xD;
                  ritonavir, ketoconazole, diltiazem], simvastatin &gt;20 mg/day, immunosuppressants.&#xD;
&#xD;
              16. Might need treatment with drugs that are prohibited during the trial: other&#xD;
                  antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors,&#xD;
                  or other drugs that may affect BP (see Error! Reference source not found.).&#xD;
&#xD;
              17. Current surgical or medical condition that might significantly alter the&#xD;
                  absorption, distribution, metabolism, or excretion of trial drugs such as prior&#xD;
                  major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel&#xD;
                  resection) or acute flare of inflammatory bowel disease within one year.&#xD;
&#xD;
              18. Individuals working &gt;2-night shifts per week.&#xD;
&#xD;
              19. Participated in any investigational drug or device trial within the previous 30&#xD;
                  days.&#xD;
&#xD;
              20. History of alcohol or drug abuse within 12 months.&#xD;
&#xD;
        At randomization visit&#xD;
&#xD;
          1. Unable to adhere to the trial procedures during the run-in period.&#xD;
&#xD;
          2. Any of the following which in the investigator's judgment may compromise the safety of&#xD;
             the participant if randomized to the trial medications:&#xD;
&#xD;
               1. High or low clinic BP levels even in the light of the values for home BP that are&#xD;
                  available for that participant. The exact levels of BP are not specified, since&#xD;
                  there is clinical uncertainty as to the relevance of BP levels which are high/low&#xD;
                  in clinic only; for example the clinical relevance of 'whitecoat hypertension' is&#xD;
                  uncertain.&#xD;
&#xD;
               2. High or low home DBP levels. The exact levels of DBP are not specified,&#xD;
                  reflecting clinical uncertainty of for example isolated diastolic hypertension.&#xD;
                  However, home DBP values of &gt;99 mmHg may typically be considered as requiring&#xD;
                  treatment intensification, and such participants would not be suitable for&#xD;
                  randomization.&#xD;
&#xD;
          3. Any abnormal laboratory value which in the judgment of the investigator could&#xD;
             interfere with the effective conduct of the trial or constitutes a significant risk to&#xD;
             the participants' well-being.&#xD;
&#xD;
          4. Fulfilling any of the exclusion criteria mentioned for the screening visit, when&#xD;
             verified again at randomization visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Rodgers, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Corstanje</last_name>
    <phone>+44 (0)7879192633</phone>
    <email>ecorstanje@george-medicines.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Milne</last_name>
    <phone>+19013900306</phone>
    <email>gmrx2gpm@georgeclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Precision Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Perez</last_name>
      <phone>813-513-2365</phone>
      <email>efpd12@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Venkata Bireddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

